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H F and CKD represent concurrent chronic disease ep-idemics.1,2 Both conditions have increasing incidenceand prevalence in older age groups as well as persons
with hypertension, diabetes mellitus, or other cardiovascular
and kidney disease risk factors.3 The presence of one condi-
tion appears to accelerate the presentation and progression of
the other; having both conditions increases the risk of hos-
pitalization, rehospitalization, need for intensive care or kid-
ney replacement therapy, and death.4–9 In addition, patients
with HF and CKD may fail to respond as predicted to con-
ventional therapies or experience increased toxicity to them.10,11Kidney International (2019) 95, 1304–1317
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The 2016 European Society for Cardiology guidelines for
managing HF define it on the basis of signs and symptoms
owing to structural and/or functional cardiac abnormalities,
resulting in a reduced cardiac output and/or elevated intra-
cardiac pressures at rest or during stress.12 Subsets of HF
include preserved ejection fraction, $50% (HFpEF); reduced
ejection fraction, <40% (HFrEF); and mid-range ejection
fraction, 40% to 49% (HFmrEF). Comorbid conditions make
the diagnosis challenging, such as CKD and end-stage kidney
disease (ESKD), as sodium and water retention contribute to
HF manifestations.13
CKD is defined on the basis of persistently reduced esti-
mated glomerular filtration rate (eGFR) of <60 ml/min per
1.73 m2 or at least 1 marker of kidney damage for>3 months.14
The latter markers include albuminuria, urine sediment ab-
normalities, histological, or structural abnormalities. HF as the
primary syndrome can experience secondary CKD, and vice
versa, or both can coexist on the basis of shared risk factors or
systemic disorders. The distinction of which disease is primary
and which is secondary may be challenging.
The incidence of de novo HF in known CKD is in the range
of 17% to 21%.15 The emergence of HF varies depending on
the degree of CKD and the modality of kidney replacement
therapy, including transplantation (Figure 1). Reduced eGFR
is associated with increased risk of all-cause mortality, car-
diovascular mortality, and hospitalization in patients with
HFpEF or HFrEF.16–18 Elevated urine albumin is prognostic
for HF outcomes, albeit to a lesser extent than reduced eGFR.
Both reduced eGFR and albuminuria can develop as a result
of HF. Thus, HF and CKD occur in a bidirectional fashion
with considerable overlap. A large meta-analysis of patients
with HFrEF and HFpEF found that w55% of both groups
had CKD G3a or higher (eGFR < 60 ml/min per 1.73 m2),
with a stepwise increase in mortality risk with the stage of
CKD.19 As severity of CKD increases, so does the prevalence
of HF. An estimated 44% of patients on hemodialysis have HF
(10% with HFpEF, 13% with HFrEF, and 21% withCKD
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Figure 1 | Cumulative probability of heart failure in
populations with chronic kidney disease (CKD), dialysis, and a
kidney transplant. CHF, congestive heart failure; ESKD, end-stage
kidney disease. Reproduced with permission from Collins AJ, Foley R,
Herzog C, et al. Excerpts from the United States Renal Data System 2007
annual data report. Am J Kidney Dis. 2008;51(1 suppl 1):S1–S320.130
Kidney International (2019) 95, 1304–1317unspecified).20 The complex and integrated pathophysiology
is depicted in Figure 2.
In CKD and ESKD, risk factors for HF include long-standing
hypertension with often worsened blood pressure (BP) control
as CKD worsens, salt and water retention causing excessive
preload, and cardiomyopathic factors including left ventricular
(LV) hypertrophy and fibrosis. In addition, there are CKD- and
ESKD-specific factors that affect afterload (increased arterial
stiffness and high output shunting through arteriovenous
fistulae or grafts) as well as load-independent factors (neuro-
hormonal activation, impaired iron utilization, anemia, demand
ischemia, profibrotic factors [e.g., fibroblast growth factor 23
{FGF-23}], inflammation, etc.).21 Arteriovenous fistulae or
grafts have been reported to worsen right ventricular hyper-
trophy, increase pulmonary pressures, associate with significant
right ventricular dilatation, and reduce right ventricular func-
tion, which are closely linked to survival.22,23
The association of CKD with mortality in HFrEF is in-
dependent of age, functional class, duration of HF, hemo-
globin, or diabetes mellitus.18 Patients with CKD are less
likely to receive guideline-directed medical therapy, likely
because of concerns about hypotension, kidney function, and
hyperkalemia.24
The epidemiology of HFpEF appears to differ from that of
HFrEF, where two-thirds of cases in the general population are
due to ischemic cardiomyopathy and the remainder is due to
nonischemic and/or idiopathic cardiomyopathy. In HFpEF
there appears to be a strong influence of age, obesity, diabetes
mellitus, and poor fitness.25 Inw25% of cases of HFpEF in the
general population, there is superimposed cardiac ischemia;
however, its role in the development of HFpEF is unknown.26,27
All-cause mortality in HFpEF with CKD is elevated.16,17,28
DIAGNOSIS
There are no accepted definitions or criteria for HF diagnosis
in CKD, and intravascular and extravascular volume overload
can occur in the absence of structural heart disease, especially
in patients with dialysis-dependent CKD. Echocardiography
can support the diagnosis of HF by providing information on
chamber volumes, ventricular systolic and diastolic function,
wall thickness, valve function, and filling pressures.12
HFpEF in nondialysis CKD
As in the general population without CKD, the diagnosis of
HFpEF in patients with nondialysis CKD is difficult and should
be supported by multiple objective measures including
impaired cardiac function with rest and exercise. Echocardi-
ography with assessment using the American Society of
Echocardiography grade of diastolic function (grades 1–4)
should be performed. Biomarkers such as B-type natriuretic
peptide (BNP) or N-terminal pro-BNP have a high negative
predictive value.29 The effect of worsening eGFR on levels of
BNP and especially N-terminal pro-BNP relates to both
impaired renal clearance and underlying cardiac abnormal-
ity.30,31 Obesity can lead to modestly lower levels of BNP and
N-terminal pro-BNP in those with HF.32 Cystatin C may1305
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Figure 2 | Pathophysiology of heart failure (HF) in chronic kidney disease (CKD) progressing to end-stage kidney disease (ESKD).
Pressure overload implies systemic hypertension. eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction.
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of its relative independence of muscle, hepatic, and dietary
contributions of creatinine. Prognostic biomarkers include
natriuretic peptides, cardiac troponins, soluble ST2 (Suppres-
sor of Tumorgenicity 2), and galectin-3.33 Biomarkers are
complementary in terms of prognostic value and may give
insight into HF phenotype. In critically ill patients, invasive
assessment of hemodynamics including measurement of the
pulmonary artery pressure, pulmonary capillary wedge pres-
sure, cardiac output, and LV end-diastolic pressure may be
required to distinguish HFpEF from other diagnoses such as
obesity-associated deconditioning, primary pulmonary hy-
pertension, high output from arteriovenous shunting, and lung
disease. Cardiopulmonary stress testing with measurement of
the peak oxygen consumption can be a helpful adjunct for
objectively assessing the degree of functional impairment and
discerning between cardiac and pulmonary dyspnea.
HFrEF in nondialysis CKD
The diagnosis of HFrEF in the population with nondialysis
CKD parallels that of the population without CKD.
Monitoring of HFrEF in CKD includes the usual standards
of care: evaluating sodium, potassium, creatinine (eGFR),
albumin-to-creatinine ratio, BNP or N-terminal pro-BNP,
troponin I or T, ST2, and galectin-3 levels, and, as is the
case in HFpEF, some select cases may justify advanced
physiological measurements such as pulmonary artery1306pressure monitoring and/or bioimpedance techniques.
Changes in volume status can be detected on physical ex-
amination, chest radiography, and lung ultrasonography.
HFpEF or HFrEF in dialysis-dependent CKD
In patients on dialysis, symptoms typical of HF, such as
paroxysmal nocturnal dyspnea, orthopnea, dyspnea, fa-
tigue, ascites, and dependent edema, may be intermittent.
It is important to consider other causes of dyspnea, such as
chronic obstructive pulmonary disease, pulmonary hyper-
tension, anemia, or obstructive sleep apnea. The Acute
Dialysis Quality Initiative has proposed a functional clas-
sification system for HF symptoms in patients with
ESKD.34
Patients with dialysis-dependent HF should undergo the
same evaluation as patients with nondialysis-dependent HF.
However, there may be additional evaluation or consider-
ations for dialysis-dependent patients.
Chest radiograph. Overall, radiographic signs are specific
but only moderately sensitive in diagnosing HF.35 The chest
radiograph can be used to screen for other sources of dyspnea,
such as pulmonary and diaphragmatic abnormalities. Given
the high rates of pneumonia in acute hospitalizations in
ESKD, the chest radiograph is prudent. Prompt resolution of
radiographic findings of interstitial infiltrates after dialysis
and/or ultrafiltration supports extracellular fluid overload as a
cause of signs and symptoms of HF, but whether this is theKidney International (2019) 95, 1304–1317
AA House et al.: HF in kidney disease: a KDIGO conference report KD IGO execu t i ve conc lu s i onsresult of structural and/or functional cardiac abnormality may
require additional diagnostic testing.
Echocardiography. Measurements of LV ejection fraction,
LV hypertrophy, right ventricular ejection fraction, chamber
dimensions, and valvular function are fundamental in man-
aging ESKD. Approximately 87% of patients with ESKD have
major abnormalities on echocardiography before initiating
treatment with dialysis.36 When possible, imaging should be
carried out when patients on dialysis are close to dry weight,
and preferably on a nondialysis day for patients on hemodi-
alysis. In addition to reduced LV ejection fraction, indicators
for LV dysfunction include LV diastolic volume index of >86
ml/m2 or LV systolic volume index of >37 ml/m2.
Electrocardiography. Electrocardiography can be used to
detect rhythm disturbances or evidence of prior myocardial
damage or pericardial disease.
In specific clinical scenarios, evaluation may include car-
diac magnetic resonance imaging, global longitudinal strain
analysis, whole-body bioimpedance technique, and extended
cardiac rhythm monitoring through wearable and implant-
able monitors. Emerging diagnostic options include pulmo-
nary artery ambulatory monitoring and thoracic impedance
monitoring. In the setting of dialysis, the role of natriuretic
peptides is unclear.37
Newly discovered HFrEF in patients undergoing dialysis
should prompt full risk stratification for an ischemic versus
nonischemic etiology. Revascularization in patients with HFrEF
in the general population is supported by 10-year outcome
data,38 but no such data exist for patients with ESKD.
TREATMENT
Prevention of incident HF
Hypertensive and glycemic control. Tight BP control,
defined as targeting systolic BP to <120 mm Hg, reduces
incident HF with LV ejection fraction $ 35%, even in the
presence of CKD.39,40 In the RENAAL (Reduction in End
Points in Non-insulin dependent diabetes mellitus with the
Angiotensin II Antagonist Losartan) diabetic nephropathy
trial, a risk reduction of 32% was observed for the first hos-
pitalization for HF in the losartan patient group versus the
placebo group.41
In patients with CKD and diabetes, poor glycemic control is a
risk factor for developing HF42 and improved glycemic control is
associated with a reduced risk of HF. In particular, sodium-
glucose cotransporter 2 inhibitors have been shown to not
only slow the progression of CKD in such patients but also
reduce the risk of hospitalizations for HF in both those with and
without a history of HF.43,44 In the EMPA-REG OUTCOME (BI
10773 [Empagliflozin] Cardiovascular Outcome Event Trial in
Type 2 Diabetes Mellitus Patients) study, empagliflozin resulted
in a 39% relative risk reduction in hospitalization for HF in
patients with type 2 diabetes mellitus and CKD G3a or higher
and/or urine albumin-to-creatinine ratio >300 mg/g.45,46 A
similar effect was seen with canagliflozin47 and dapagliflozin.48
Whether glycemic control has a direct effect in preventing HF
is unclear, as sodium-glucose cotransporter 2 inhibitors also leadKidney International (2019) 95, 1304–1317to reductions in BP and body weight, promote diuresis, and have
strong off-target effects on the cardiac Naþ/Hþ exchanger.49
Treatment of existing HF
There are no proven treatments for HFpEF, including in the
setting of CKD.50 Medications that can reduce adverse out-
comes associated with HFrEF include angiotensin-
converting enzyme inhibitors (ACEis),51 angiotensin II
receptor blockers (ARBs), angiotensin receptor neprilysin
inhibitors, b-blockers, and mineralocorticoid receptor an-
tagonists (MRAs).52 However, it cannot be assumed that
drugs with proven efficacy in HFrEF have the same benefits
in HFpEF.51–55
Although strategies for treating HF are the same in patients
with or without CKD, its presence raises special consider-
ations, particularly for patients with eGFR < 30 ml/min per
1.73 m2 (serum creatinine level $2.5–3.0 mg/dl), who have
largely been excluded from clinical trials, and in whom the
risk of toxicity may significantly complicate therapy. Therapy
for HFrEF can cause eGFR to vary, so when eGFR declines
from >60 to <60 ml/min per 1.73 m2 (i.e., CKD G3a or
higher) it can be unclear if this truly represents CKD versus a
transient decline due to hemodynamic and neurohormonal
factors. In addition, serum creatinine levels do not solely
reflect kidney function, thus further complicating the inter-
pretation of eGFR measurement. As such, measurement of
cystatin C levels can assist with the interpretation given the
variability in creatinine levels. It is likely that biomarkers of
true kidney damage in addition to functional markers will
play an important role in the future. Identification of true
kidney injury versus transient azotemia would dramatically
aid in decisions on diuretics and other agents in goal-directed
medical therapy.
b-Blockers. The Metoprolol CR/XL Randomized Inter-
vention Trial in Chronic HF (MERIT-HF) trial randomized
patients with symptomatic HFrEF to metoprolol or placebo
and included many patients with eGFR < 45 ml/min per
1.73 m2. The hazard ratio for total mortality was 0.41 in
favor of metoprolol for the CKD subgroup and demon-
strated higher risk reduction than did the reference group
with eGFR > 60 ml/min per 1.73 m2.56 A similar analysis
was performed in the CIBIS-II (Cardiac Insufficiency
Bisoprolol Study II) study, which included patients having
a serum creatinine level up to 300 mmol/l (3.4 mg/dl) and
demonstrated sustained benefit of bisoprolol with wors-
ening kidney function.57 A small study of carvedilol in
patients with dialysis-dependent CKD and HFrEF also
conferred a mortality benefit.58 Therefore, it seems
reasonable to use b-blockers for managing HFrEF in pa-
tients with CKD, except for b-blockers that have significant
renal excretion and have the potential for overexposure,
such as atenolol, nadolol, or sotalol.59 Atenolol can be used
as part of the management approach for hypertension and
coronary disease if given 3 times per week in ESKD during
hemodialysis.60 Consideration should be given to the po-
tential for dialyzability of certain b-blockers, as a 1.4-fold1307
KDIGO execu t i ve conc lu s i ons AA House et al.: HF in kidney disease: a KDIGO conference reportincreased mortality risk was observed in the group treated
with highly dialyzable b-blockers such as metoprolol.61
Angiotensin blockade. Both ACEis and ARBs can lead to
decreased GFR in patients with HFpEF or HFrEF. In patients
with HFrEF, the benefit of angiotensin blockade in terms of
mortality and other important outcomes is maintained62;
however, observational trials in patients with HFpEF and
worsening kidney function due to ACEis or ARBs have an
increased mortality risk without experiencing improved
outcome,63,64 although these results have not been consis-
tent.65 ARBs can be considered for those who are ACEi
intolerant. The Survival And Ventricular Enlargement (SAVE)
study of captopril versus placebo post–myocardial infarction
enrolled patients with HFrEF and serum creatinine level #2.5
mg/dl at baseline, of whom approximately one-third and one-
tenth of patients had eGFR < 60 and < 45 ml/min per 1.73
m2, respectively. The superiority of captopril was maintained
in patients with CKD.66 Other trials of ACEis and ARBs re-
ported similar results in patients with CKD G3a and HFrEF.67
The angiotensin receptor neprilysin inhibitor LCZ696 has also
demonstrated a hemodynamic effect in preserving GFR, with
1 study reporting smaller eGFR decline in patients with
HFpEF on LCZ696 versus valsartan after 36 weeks of treat-
ment.68 However, urinary albumin-to-creatinine ratios
showed increases with LCZ696 versus valsartan. Figure 3
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1308Azotemia alone in the setting of diuresis should not
necessarily result in changes to or withdrawal of ACEis or
ARBs because their removal may lead to worse outcomes.69,70
Diuretics. Thiazide diuretics are a mainstay of BP control
in the general population and commonly advanced to loop
diuretics in the setting of CKD. Important considerations in
patients hospitalized for decompensated HF on a twice daily,
chronic oral loop diuretic regimen include (i) dosing, (ii)
duration, and (iii) whether to change from oral to i.v.
Increased i.v. doses of furosemide and continuous infusions
may be used to relieve congestion. The Diuretic Optimization
Strategies Evaluation (DOSE-AHF) study demonstrated that a
high-dose strategy could improve dyspnea scores, weight
change, and net fluid loss at 72 hours whereas a low-dose
group was less likely to convert from i.v. to oral and more
likely to require a dose increase. There was an increased fre-
quency of early increased serum creatinine level of $0.3 mg/
dl in the high-dose group, but no appreciable difference in
kidney function over 60 days between any of the study
groups.71 Torsemide may have an advantage over furosemide,
with longer half-life, better bioavailability, and potential for
reducing myocardial fibrosis,72,73 but this requires
confirmation.
MRAs. In patients with HF and CKD G3a-G3b, MRAs are
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subjects with ejection fraction < 35% but excluded patients
with serum creatinine level $ 2.5 mg/dl or serum potassium
level > 5.0 mEq/l.75 However, a sizable subgroup of patients
in RALES had eGFR < 60 ml/min per 1.73 m2, and these
patients experienced a similar reduction with spironolactone
in all-cause death or hospitalizations for HF as with those
who had eGFR > 60 ml/min per 1.73 m2,76 although they
more frequently had hyperkalemia, reduction of >30% in
eGFR, dose reduction, or discontinuation. Similar results have
been shown with eplerenone.67 Data on the use of MRAs for
the treatment of HF (either HFrEF or HFpEF) in patients
with CKD G4-G5 or patients on dialysis are of limited
quality.77 One observational study identified a significantly
increased adjusted risk of death or hospitalization for HF in
patients with CKD G5 treated with spironolactone.78 An
ongoing randomized clinical trial (RCT) of spironolactone in
patients with HFrEF undergoing hemodialysis should inform
practice in the future (ClinicalTrials.gov identifier:
NCT01848639).
In a study of patients with HFrEF and type 2 diabetes
mellitus and/or CKD G3a who were randomized to 1 of 5
different doses of finerenone (a nonsteroidal MRA) versus
eplerenone, patients randomized to the highest dose of
finerenone experienced a decrease in the secondary composite
endpoint of death, cardiovascular hospitalization, or emer-
gency department visit for worsening HF without worsening
hyperkalemia or kidney function.79 Confirming these prom-
ising results in a larger study of patients with CKD G4 would
be valuable.C
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Kidney International (2019) 95, 1304–1317Hyperkalemia. Because of concerns about hyperkalemia,
there is a strong underutilization of renin-angiotensin-
aldosterone system inhibitors and a high rate of discontinu-
ation in patients with HF and CKD.69,80 In a small study of
patients with CKD and HF who were hyperkalemic and on
renin-angiotensin-aldosterone system inhibitors, 4 weeks of
treatment with patiromer led to a mean reduction of 1.06 
0.05 mEq/l in serum potassium levels and lower rates of
recurrent hyperkalemia as compared with placebo.81 In
another study that included 69% patients with eGFR <60 ml/
min per 1.73 m2, 48 hours of open-label treatment with so-
dium zirconium cyclosilicate resulted in normokalemia in
98% of patients. In a subsequent study, the serum potassium
level was significantly lower during days 8 to 29 with sodium
zirconium cyclosilicate.82 However, edema was observed more
frequently at the highest dose (15 g).82,83 It remains unproven
that pharmacological control of potassium levels can lead to
increased ACEi/ARB/MRA utilization and in turn improve
HF or CKD outcomes. It is also unknown whether deliber-
ately lowering potassium levels would be helpful or harmful
in the context of HF. Some have suggested that MRA may be
beneficial on the basis of increasing serum potassium level,
whereas others argue that the high serum potassium level
causes further compensatory increase in aldosterone, which
in turn is implicated in the pathophysiology of both HF and
CKD. Only long-term RCTs will determine the merits of
potassium reduction in this setting.
LV assist devices. Renal dysfunction is common in pa-
tients referred for mechanical circulatory support (MCS),
and there are currently no diagnostic tests to distinguishHD × 6
nocturnal
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Table 1 | Available evidence of the prevalence of HF before kidney transplantation and outcomes after transplantation
Reference Design and participants Measure to identify HF
Prevalence of HF or LV
systolic dysfunction before
kidney transplantation Outcomes after HFa
Wu et al.99  Retrospective, longitudinal
 712 recipients of KTx at 1 U.S.
center (1998–2003)
 Extraction of
comorbidities data from
EMRs
 HF 11.9% at the time of
KTx
Faravardeh et al.100  Retrospective, longitudinal
 4482 recipients of KTx at 1 U.S.
center (1963–2012)
 Details of local clinical
data collection unknown
 5.8% at the time of KTx
 3.9% in patients aged
<50 yr, 8.4% in patients
aged 50–64 yr, 12.1% in
patients aged $65 yr
 HF increased mortality after
KTx (HR, 1.84; 95% CI, 1.20–
2.83 in patients aged $65 yr;
HR, 1.63, 95% CI, 1.24–2.15 in
patients aged <50 yr; no
increased mortality observed
in patients aged 50–64 yr
 HF: an independent risk fac-
tor for graft failure in patients
aged <50 and $65 yr
Siedlecki et al.101  Retrospective, longitudinal
 653 recipients of KTx at 1 U.S.
center (1998–2005)
 Recipients of KTx who had
SPECT perfusion scans for
KTx evaluation
 Clinical database
 18% with LVEF #45%
(mean LVEF, 36.7%
 6.7%)
 LVEF #45% was associated
with increased cardiac mor-
tality (HR, 4.8; 95% CI, 2.1–
11.2), total mortality (HR, 2.0;
95% CI, 1.2–3.5), and cardiac
complications (HR, 1.7; 95%,
CI 1.1–2.8) after KTx
 Mean time to cardiac-related
death: 1.5  1.7 yr after KTx
Lentine et al.102  Retrospective, longitudinal
 27,011 Medicare-insured U.S.
recipients of KTx (1995–2001)
without indication of HF before
transplantation
 Diagnosis codes on
Medicare billing claims
(inpatient and outpatient
HF)
 Development of HF on
the transplant waiting list:
6.5%, 12%, and 32% at 6,
12, and 36 mo
Lentine et al.103  Retrospective, longitudinal
 1102 recipients of KTx at 1 U.S.
center (1991–2004)
 Physician-reported
diagnoses in the center’s
clinical database
 Development of HF on
the transplant waiting list:
46% at 36 mo
CI, confidence interval; EMR, electronic medical record; HF, heart failure; HR, hazard ratio; KTx, kidney transplant; LV, left ventricular; LVEF, left ventricular ejection fraction;
SPECT, single photon emission computed tomography; U.S., United States.
aReported HRs are multivariate.
KDIGO execu t i ve conc lu s i ons AA House et al.: HF in kidney disease: a KDIGO conference reportirreversible from reversible forms of renal dysfunction in such
patients. Although most patients, including those with renal
dysfunction, experience early improvement in kidney function
with MCS, this improvement is often transient.84 Venous
congestion, right ventricular dysfunction, and reduced pulsatility
are potential mechanisms involved in resurgence of renal
dysfunction after MCS. Although there is no clearly preferred
methodof kidney replacement therapy inMCS, peritoneal dialysis
has advantages in MCS and non-MCS HF with sustained daily
ultrafiltration, fewer volume-related preload issues, home acces-
sibility, and reduced cost. Patients with ESKD undergoing MCS
have significantly worse outcomes than do those without ESKD.85
Adjunctive and emerging approaches. Improved diagnosis
and treatment of sleep apnea, obesity management, nutrition
management, physical activity, sodium restriction (and
possibly fluid restriction), and assessments for chronotropic
incompetence may be helpful in reducing symptoms and
improving functioning for patients with HF and CKD. In the
setting of atrial fibrillation, permissive rate control and car-
dioversion are reasonable strategies.1310Treatment of CKD-related conditions and dialysis
Iron deficiency and anemia. Erythropoiesis-stimulating
agents have no effect on the prevention or treatment of HF in
patients with CKD.80,86 Yet for patients with chronic HF and
iron deficiency with or without anemia, treatment with i.v.
ferric carboxymaltose improves symptoms, functional ca-
pacity, and quality of life.87 In the CONFIRM-HF (Ferric
CarboxymaltOse evaluatioN on perFormance in patients with
IRon deficiency in coMbination with chronic Heart Failure)
study of patients with LV ejection fraction #45%, treatment
of iron deficiency with ferric carboxymaltose for >1 year was
associated with a significant reduction in the risk of hospi-
talization for worsening HF.88 In the FAIR-HF (Ferinject
Assessment in patients with IRon deficiency and chronic
Heart Failure) trial in patients with HF and iron deficiency,
treatment with ferric carboxymaltose was associated with an
increase in eGFR compared with placebo.89 A recent meta-
analysis showed that hospitalizations for HF and mortality
were significantly decreased in the iron-treated group, of
whom >40% had eGFR < 60 ml/min per 1.73 m2 and ironKidney International (2019) 95, 1304–1317
Table 2 | Risk factors for HF after kidney transplantation
Risk factor
Rigatto
et al.104
Abbott
et al.105
Lentine
et al.102
Risk factors for HF in
the general
population42,106–108
Increased age X X X X
Sex X Increased in male
patients (increased
in female patients
in the absence of
MI)
Increased BMI X X X
Unemployment X
CVD before KTx X X Prevalent coronary
heart disease and
prior MI
MI after KTx X X Prevalent coronary
heart disease and
prior MI
Smoking history X X
Diabetes X X X X
Anemia X X X
Hypoalbuminemia X X
Hypertension X X X
African American race X X
Increased duration of
dialysis before KTx
X NA
Deceased donor
kidney
X NA
Increased donor age X NA
Delayed graft function X X NA
Graft failure X X NA
Allograft rejection X X Chronic kidney
disease
Donor CMV positive X NA
BMI, body mass index; CMV, cytomegalovirus; CVD, cardiovascular disease; HF, heart
failure; KTx, kidney transplant; MI, myocardial infarction; NA, not applicable.
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ferrin saturation is <20%) irrespective of hemoglobin level.90
Patients with HF and CKD can be considered for receiving
parenteral iron given the proven safety record in patients with
advanced CKD.91
Hypoxia-inducible factor prolyl hydroxylase inhibitors are
being evaluated for their ability to treat anemia in CKD, and
intriguing data suggest a possible role for the prevention or
attenuation of cardiac ischemic injury.92
Mineral and bone disorders. There are limited data from
RCTs, but cinacalcet treatment has been associated with
modest reductions in the time to first episode of HF in pa-
tients on hemodialysis.93
Macro- and micronutrients. Maintenance of lean tissue
through adequate macronutrient intake of protein, essential
amino acids, and essential fatty acids is viewed as desirable,
and adequate levels of micronutrients including water- and
fat-soluble vitamins, trace minerals, and cofactors are also
considered to be important.
Mode of dialysis. There are no studies of interventions
that use the development of de novo HFrEF or HFpEF as an
outcome in the population on dialysis. To date, it has not
been feasible to randomize patients to modality type.94
Increasing the frequency of dialysis sessions, as in short
daily hemodialysis, reduces LV mass and lowers the risk of
cardiovascular death and hospitalizations.95 Patients under-
going home dialysis have a markedly reduced risk of hospi-
talization for HF and cardiovascular mortality (41% lower
risk of HF, fluid overload, and cardiomyopathy).95 As shown
in Figure 4, home nocturnal hemodialysis 6 times per week is
next best after kidney transplantation and normal func-
tioning kidneys for clearance of urea from water. These
benefits are juxtaposed against a higher risk of vascular ac-
cess issues and infection-related hospitalization.96 Recurrent
dialysis-induced ischemic injury is associated with regional
wall motion abnormalities and the development and wors-
ening of HF,97 and therefore conditions of the dialysis
treatment itself may influence HF. Evidence from a small
study suggests dialysate cooling may slow the progression of
hemodialysis-associated cardiomyopathy by reducing
recurrent ischemic injury.98 Thus far there are no RCTs to
inform the benefits of peritoneal dialysis versus hemodial-
ysis. Management of the sodium concentration in dialysis
solutions requires careful consideration in dialysis-
dependent patients with HF, as it may present an addi-
tional sodium load. Strategies to maintain, where possible,
residual kidney function are desirable, as this can mitigate
some of the significant hemodynamic and fluid shifts that
occur with volume removal during dialysis.
PATIENTS WITH A KIDNEY TRANSPLANT
Incidence and prevalence of HF in recipients of kidney
transplant
In patients with a kidney transplant, HF has been most
commonly defined and identified in administrative and
clinical databases and less frequently identified withKidney International (2019) 95, 1304–1317diagnostic testing such as echocardiography. Data on pre-
transplant HF prevalence and prognosis are sparse, but the
prevalence of HF/LV systolic dysfunction in patients referred
or wait-listed for transplantation may be as high as 25%
(Table 1).99–103 HF at the time of transplantation is associated
with a higher risk of mortality, cardiovascular events, and
graft failure.100–102
On the basis of Medicare billing claims data, the incidence of
posttransplant de novo HF is w18% at 3 years.102 Several risk
factors have been shown to be associated with clinical HF after1311
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ated with lower patient and graft survival (Supplementary
Table S1).102–105,109
Diagnosis and screening of HF in recipients of kidney
transplant
There is little or no evidence of whether to obtain a screening
echocardiogram to assess LV function for all transplant can-
didates. However, it is reasonable to obtain an echocardio-
gram if there are symptoms of HF, history of cardiovascular
disease, or hemodynamic instability on dialysis. The approach
to de novo HF in transplant recipients is the same as that for
the general population, including evaluation for coronary
artery disease.110Table 3 | Future research recommendations
 Acquire a better understanding of the pathophysiology of HF in CKD. Phy
plasma serum creatinine, blood urea nitrogen, and limited urine tests is in
reserve, or the ability of the kidneys to increase filtration, are needed. An un
needed. Conversely, methods of assessing inflammation, irreversible fibros
recoverability of AKI superimposed on CKD. The clinical examination can be
volume and red blood cell volume, degree of pulmonary congestion, and v
treatment with i.v. loop diuretics or ultrafiltration are needed. Variation in
first few doses while others do not. Investigating possible systemic mechan
of the processes by which the kidneys retain salt and water and how this
worthwhile.
 Reevaluate the pathophysiology of the progression of HF. This includes
biomarkers (e.g., neurohormonal activation, bone metabolism, inflammatio
and symptomatic patients.
 Identify appropriate kidney outcomes for HF trials and position them as
trials of HF interventions should focus on prespecified subgroups with eG
 Refine detection of AKI using measures of kidney filtration and markers
 Examine and include patient-oriented outcomes, especially for symptom
 Develop and test better markers of initiation, persistence, and recover
Understanding the role of AKI in the prediction and management of diure
 Study novel diuretic strategies in patients with HFrEF with more accurate
and continued congestion.
 Identify the best means for adjusting loop diuretics, whether by blood bi
use of diuretics in HF with CKD in the hope of reducing hospitalizations f
 Examine new potassium-binding drugs in patients with eGFR < 30 ml/m
binding drugs allow higher use or doses of RAAS blockers and whether th
whether and how potassium-lowering agents can reduce potassium swing
 Compare various dialysis modalities and their frequency for optimizing
 Address and overcome the difficulty in randomizing patients to periton
 Determine the optimal timing for initiating dialysis in the setting of HFr
develop diuretic resistance could benefit from starting dialysis early.
 Find methods of achieving volume control during dialysis while still ens
 Evaluate wearable devices that monitor fluid status, heart rhythm, etc.
 Design and conduct an adequately powered observational study of clin
transplantation.
 Determine which patients should undergo a simultaneous heart-kidney
renal recovery posttransplant.
 Investigate the degree to which the following comorbid conditions con
artery disease, valvular disease, diabetes, atrial fibrillation, sleep apnea
chronic lung disease, and hypertension.
 Investigate technologies to better phenotype patients and target the
assessment could include genomics, metabolomics, cardiovascular hemod
metabolism including plasma refill, and heart-kidney signaling and regula
 Evaluate the effects of exercise, weight loss, diet, and possibly treatmen
 Ascertain approaches to reduce protein energy wasting, sarcopenia, and
the prevention of HF and the attenuation of both HF and CKD.
 Obtain a better understanding of best practices for ligating AV fistulas fo
AKI, acute kidney injury; AV, arteriovenous; CKD, chronic kidney disease; eGFR, estimate
heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection
1312HF treatment in recipients of kidney transplant
Transplant recipients with HF should be treated as they would
be treated in the general population. There have been no
definitive interventional studies of ACEis or ARBs, MRAs, b-
blockers, calcium channel blockers, nitrates, vasodilators, or
angiotensin receptor neprilysin inhibitors in the treatment of
HF in recipients of kidney transplant. In a small RCT of re-
cipients of kidney transplant with LV hypertrophy, lisinopril
reduced LV mass index compared with placebo.111 There are
no reports evaluating interventions that could possibly pre-
vent or delay development of de novo HF in patients with a
kidney transplant, nor are there trials in patients with a
kidney transplant that have included HF as an endpoint. In
some patients with a kidney transplant, management of HF issiological and imaging tests are needed for kidney disease. Reliance on the
adequate to advance the field. Methods to assess the kidney functional
derstanding of when reduced renal filtration is adaptive or maladaptive is
is, and loss of functioning nephrons would assist in understanding the
improved by objective measurements of volume status including plasma
enous capacitance. Studies to unveil the determinants of plasma refill after
plasma refill likely explains why some patients respond favorably after the
isms of both heart and kidney disease and gaining a better understanding
relates to myocardial dysfunction in systole and diastole would be
examining the role of serial imaging of right/left ventricular function and
n, fibrosis, and kidney injury) in prognosis and treatment in asymptomatic
prespecified endpoints (i.e., progression of CKD and eGFR slopes). Future
FR < 30 ml/min per 1.73 m2.
of kidney damage.
control, and design shared decision-making aids.
y of AKI. AKI biomarkers have not been adequately studied in acute HF.
tic resistance will be important for acute HF.
methods to detect volume overload in order to avoid both hypotension
omarker measurement or hemodynamic assessment. This will help guide
or HF and perhaps cardiovascular death.
in per 1.73 m2. It would also be useful to know whether the potassium-
is leads to improved outcomes. It would also be important to examine
s when patients are undergoing hemodialysis.
ultrafiltration and maintaining euvolemia.
eal dialysis or ultrafiltration trials.
EF and HFpEF. There is reason to hypothesize that the subgroup that will
uring patients receive optimal cardioprotective medications.
ical and echocardiographic determinants of HF in patients referred for
transplant versus a heart transplant alone with watchful waiting for
tribute to HF physiology in patients with ESKD: hypertension, coronary
, cachexia/sarcopenia, anemia, iron deficiency, mineral metabolism,
m for specific interventional strategies. Such domains of phenotypic
ynamics, myocardial energetics, neurohormonal milieu, salt and water
tion.
t of sleep apnea in the prevention of HF in patients with CKD.
cachexia. Research is needed to better understand the role of nutrition in
r high output cardiac failure: location, flow, determining when to ligate.
d glomerular filtration rate; ESKD, end-stage kidney disease; HF, heart failure; HFpEF,
fraction; RAAS, renin-angiotensin-aldosterone system.
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Figure 5 | Positioning of heart failure (HF) therapies according to left ventricular ejection fraction and renal filtration function. ACEi,
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, b-blocker; CKD G5D, chronic kidney disease glomerular filtration
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prevent the use of ACEis, ARBs, and MRAs. Counteracting
therapies such as patiromer or sodium zirconium cyclosilicate
will require evaluation in this population, as there is potential
for interference with absorption of certain medications.
Concern about reduction in eGFR should not automati-
cally lead to withholding of otherwise beneficial treatments of
HFrEF. A unique exacerbating factor may be the ongoing
presence of an “unnecessary” arteriovenous fistula, the liga-
tion of which should be considered in recipients with
symptoms of HF, a high cardiac output hemodynamic profile,
and high arteriovenous fistula flow (1.5–2.0 l/min and arte-
riovenous fistula flow > 30% cardiac output).112
Effects of kidney transplantation on cardiac structure and
function
Reports have documented reversal of clinical cardiac
dysfunction and improvement in echocardiographic param-
eters after kidney transplantation,113–127 supporting the
notion of a potentially reversible “uremic cardiomyopathy”
(Supplementary Table S2). Reversal is less likely in patients
who have been dialyzed for long periods of time.114 Trans-
plant candidates should thus not be excluded solely on theKidney International (2019) 95, 1304–1317basis of LV systolic dysfunction and, in some circumstances,
should be considered for priority wait-listing. However, there
exists a need for more long-term studies with prospective
follow-up of LV structure and function before and after
kidney transplantation to evaluate consecutive patients in an
unbiased fashion.
Simultaneous kidney-heart transplant
Patients with severe HF who are dependent on chronic dial-
ysis may benefit from a simultaneous kidney-heart transplant.
In an analysis of U.S. registry data, 5-year posttransplant
survival was higher in dialysis-dependent patients with end-
stage HF who received a simultaneous kidney-heart trans-
plant compared with heart transplant alone (75% vs. 51%).128
Survival benefits were present, although to a lesser extent, in
patients with renal dysfunction and end-stage HF not
dependent on dialysis who received a kidney-heart trans-
plant.129 Given the absence of robust data on patient selection
for simultaneous kidney-heart transplantation, it is reason-
able to state that transplantation of both organs must be
weighed against the possibility of recovering kidney function
with heart transplantation alone, and selection bias must be
considered in interpreting these observational data.1313
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Table 3 outlines the prioritized research recommendations
whose outcomes would most likely improve future clinical
practice.
CONCLUSION
A multidisciplinary approach is vital for understanding the
mechanistic and clinical data concerning HF in CKD. Clearly,
high-quality data are lacking on all aspects of HF (patho-
physiology, epidemiology, diagnosis, prevention, and treat-
ment) specific to the population of patients with advanced
nondialysis CKD as well as patients undergoing dialysis and
transplantation. Figure 5 depicts a representation of the
relative benefits of evidence-based therapy of HF across a
continuum of kidney function. It is highly recommended that
nephrologists and cardiologists partner to design and conduct
clinical trials and that trials be as integrative as possible.
Because HF in CKD appears to be a complex disease or set of
syndromes, it is prudent to integrate clinical history, pheno-
typic assessment with biomarkers and high-quality imaging,
and treatment paradigms that are both comparable and sus-
tainable. It is important to avoid medication toxicity and
complications with cardiovascular or renal procedures in the
setting of HF and CKD. The interpretation of azotemia as
representing kidney damage versus transient worsening kid-
ney function is one of the great challenges facing clinicians
today and calls for a strong mandate for use of biomarkers
beyond serum creatinine and blood urea nitrogen. In the
future, it will be beneficial to include patient-oriented out-
comes as well as end-of-life preferences when evaluating
therapeutic strategies, particularly in patients who are dialysis
dependent.
APPENDIX
Other conference participants
Ali K. Abu-Alfa, Lebanon; Kerstin Amann, Germany; Kazutaka Aonuma,
Japan; Lawrence J. Appel, USA; Colin Baigent, UK; George L. Bakris, USA;
Debasish Banerjee, UK; John N. Boletis, Greece; Biykem Bozkurt, USA; Javed
Butler; USA; Christopher T. Chan, Canada; Maria Rosa Costanzo, USA; Ruth
F. Dubin, USA; Gerasimos Filippatos, Greece; Betty M. Gikonyo, Kenya; Dan
K. Gikonyo, Kenya; Roger J. Hajjar, USA; Kunitoshi Iseki, Japan; Hideki Ishii,
Japan; Greg A. Knoll, Canada; Colin R. Lenihan, USA; Krista L. Lentine, USA;
Edgar V. Lerma, USA; Etienne Macedo, USA; Patrick B. Mark, UK; Eisei Noiri,
Japan; Alberto Palazzuoli, Italy; Roberto Pecoits-Filho, Brazil; Bertram Pitt,
USA; Claudio Rigatto, Canada; Patrick Rossignol, France; Soko Setoguchi,
USA; Manish M. Sood, Canada; Stefan Störk, Germany; Rita S. Suri, Canada;
Karolina Szummer, Sweden; Sydney C.W. Tang, Hong Kong, China; Navdeep
Tangri, Canada; Aliza Thompson, USA; Krishnaswami Vijayaraghavan, USA;
Michael Walsh, Canada; Angela Yee-Moon Wang, Hong Kong, China;
Matthew R. Weir, USA
DISCLOSURE
CW declared having received consultancy fees from Bayer, Boehringer
Ingelheim, GSK, and Sanofi-Genzyme; speaker honoraria from AstraZeneca,
Boehringer Ingelheim, Lilly, MSD, Novartis, and Sanofi-Genzyme; and research
support from Sanofi-Genzyme. MJS declared having received research support
from Akebia Therapeutics (monies paid to institution) and the National
Institutes of Health. ILP declared having received consultancy fees from
Relypsa; and research support from Food & Drug Administration, Center for
Devices and Radiological Health. CWM declared having received consultancy
fees from Baxter; and research support from Baxter, Canadian Institutes of
Health Research, Heart and Stroke Foundation, Intellomed, and Kidney1314Foundation of Canada. PK declared having received consultancy fees from
Boehringer Ingelheim; employment fees from Quanta Dialysis Technologies;
and research support from Canadian Institutes of Health Research. AD declared
having received speaker honoraria from PeerView Institute for Medical
Education and research support from the National Institutes of Health. CRD
declared having received consultancy fees from Abbott Diagnostics, Ortho
Clinical, Roche Diagnostics, and Siemens; speaker honoraria from Roche
Diagnostics; and research support from the National Institutes of Health. JGFC
declared having received consultancy fees from AstraZeneca, Bayer, BMS, GSK,
Medtronic, MyoKardia, Novartis, Philips, Sanofi, Servier, Stealth
BioTherapeutics, Torrent Pharmaceuticals, and Vifor; speaker honoraria from
AstraZeneca, BMS, GSK, Medtronic, MyoKardia, Novartis, Philips, Sanofi, Servier,
Stealth BioTherapeutics, Torrent Pharmaceuticals, and Vifor; and research
support from Amgen, Bayer, BMS, Medtronic, Novartis, Pharmacosmos, Pharma
Nord, Stealth BioTherapeutics, Torrent Pharmaceuticals, and Vifor. SDA
declared having received consultancy fees from Bayer, Boehringer Ingelheim,
Novartis, Servier, and Vifor; speaker honoraria from Bayer, Boehringer
Ingelheim, and Vifor; and research support from Abbott Vascular and Vifor.
CAH declared having received consultancy fees from AbbVie, Amgen,
AstraZeneca, Corvidia, DiaMedica, FibroGen, Janssen, Oxford University,
OxThera, Pfizer, Relypsa, and Sanifit; stock equity from BMS, Boston Scientific,
General Electric, Johnson & Johnson, and Merck; and research support from
Amgen, BMS, CARSK (Canadian-Australasian Randomised Trial for Screening
Kidney Transplant Recipients for Coronary Artery Disease), the National Heart,
Lung, and Blood Institute, the National Institutes of Health, Relypsa, and Zoll.
DCW declared having received consultancy fees from Akebia Therapeutics,
AstraZeneca, Amgen, Boehringer Ingelheim, GSK, Janssen, and Vifor Fresenius;
speaker honoraria from Amgen and Vifor Fresenius; and research support from
AstraZeneca. WCW declared having received consultancy fees from Akebia
Therapeutics, AMAG, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and
ZS Pharma; speaker honoraria from FibroGen; and research support from the
National Institutes of Health. All the other authors declared no competing
interests.
ACKNOWLEDGMENTS
The conference was sponsored by KDIGO and supported in part by
unrestricted educational grants from Abbott, Akebia Therapeutics,
AMAG Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim,
Corvidia, Fresenius Medical Care, Keryx Biopharmaceuticals, NxStage,
Relypsa, Roche, Sanifit, and Vifor Fresenius Medical Care Renal
Pharma. We thank Jennifer King, PhD, for assistance with manuscript
preparation.SUPPLEMENTARY MATERIAL
Table S1. Available evidence on the incidence and outcomes of HF
after kidney transplantation.
Table S2. Selected studies evaluating kidney transplantation and
reversal of structural and functional cardiac dysfunction.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
REFERENCES
1. McCullough PA, Philbin EF, Spertus JA, et al. Confirmation of a heart
failure epidemic: findings from the Resource Utilization Among
Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60–
69.
2. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney
disease—a systematic review and meta-analysis. PLoS One. 2016;11:
e0158765.
3. McCullough PA, Bakris GL, Owen WF Jr, et al. Slowing the progression
of diabetic nephropathy and its cardiovascular consequences. Am Heart
J. 2004;148:243–251.
4. McCullough PA, Kellum JA, Haase M, et al. Pathophysiology of the
cardiorenal syndromes: executive summary from the eleventh
consensus conference of the Acute Dialysis Quality Initiative (ADQI).
Contrib Nephrol. 2013;182:82–98.
5. Haase M, Muller C, Damman K, et al. Pathogenesis of cardiorenal
syndrome type 1 in acute decompensated heart failure: workgroup
statements from the eleventh consensus conference of the Acute
Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013;182:99–116.Kidney International (2019) 95, 1304–1317
AA House et al.: HF in kidney disease: a KDIGO conference report KD IGO execu t i ve conc lu s i ons6. Cruz DN, Schmidt-Ott KM, Vescovo G, et al. Pathophysiology of
cardiorenal syndrome type 2 in stable chronic heart failure: workgroup
statements from the eleventh consensus conference of the Acute
Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013;182:117–136.
7. Bagshaw SM, Hoste EA, Braam B, et al. Cardiorenal syndrome type 3:
pathophysiologic and epidemiologic considerations. Contrib Nephrol.
2013;182:137–157.
8. Tumlin JA, Costanzo MR, Chawla LS, et al. Cardiorenal syndrome type 4:
insights on clinical presentation and pathophysiology from the
eleventh consensus conference of the Acute Dialysis Quality Initiative
(ADQI). Contrib Nephrol. 2013;182:158–173.
9. Mehta RL, Rabb H, Shaw AD, et al. Cardiorenal syndrome type 5: clinical
presentation, pathophysiology and management strategies from the
eleventh consensus conference of the Acute Dialysis Quality Initiative
(ADQI). Contrib Nephrol. 2013;182:174–194.
10. Di Lullo L, House A, Gorini A, et al. Chronic kidney disease and
cardiovascular complications. Heart Fail Rev. 2015;20:259–272.
11. House AA. Cardiorenal syndrome: new developments in the
understanding and pharmacologic management. Clin J Am Soc Nephrol.
2013;8:1808–1815.
12. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the
diagnosis and treatment of acute and chronic heart failure: the Task
Force for the diagnosis and treatment of acute and chronic heart failure
of the European Society of Cardiology (ESC). Developed with the
special contribution of the Heart Failure Association (HFA) of the ESC.
Eur Heart J. 2016;37:2129–2200.
13. Ellison DH. Treatment of disorders of sodium balance in chronic kidney
disease. Adv Chronic Kidney Dis. 2017;24:332–341.
14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.
KDIGO 2012 clinical practice guidelines for the evaluation and
managment of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
15. Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk
factor for incident heart failure: the Atherosclerosis Risk in Communities
(ARIC) study. J Am Soc Nephrol. 2007;18:1307–1315.
16. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of
outcome in a broad spectrum of patients with heart failure. Circulation.
2006;113:671–678.
17. Smith DH, Thorp ML, Gurwitz JH, et al. Chronic kidney disease and
outcomes in heart failure with preserved versus reduced ejection
fraction: the Cardiovascular Research Network PRESERVE Study. Circ
Cardiovasc Qual Outcomes. 2013;6:333–342.
18. Lofman I, Szummer K, Dahlstrom U, et al. Associations with and
prognostic impact of chronic kidney disease in heart failure with
preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail.
2017;19:1606–1614.
19. McAlister FA, Ezekowitz J, Tarantini L, et al. Renal dysfunction in
patients with heart failure with preserved versus reduced ejection
fraction: impact of the new Chronic Kidney Disease-Epidemiology
Collaboration Group formula. Circ Heart Fail. 2012;5:309–314.
20. United States Renal Data System. Annual Data Report 2016: Chapter 9:
cardiovascular disease in patients with ESRD. Available at: https://www.
usrds.org/2016/view/v2_09.aspx?zoom_highlight¼dialysisþ
heartþfailure. Accessed April 7, 2019.
21. Pecoits-Filho R, Bucharles S, Barberato SH. Diastolic heart failure in
dialysis patients: mechanisms, diagnostic approach, and treatment.
Semin Dial. 2012;25:35–41.
22. Reddy YNV, Obokata M, Dean PG, et al. Long-term cardiovascular
changes following creation of arteriovenous fistula in patients with end
stage renal disease. Eur Heart J. 2017;38:1913–1923.
23. Eckardt KU, Bansal N, Coresh J, et al. Improving the prognosis of
patients with severely decreased glomerular filtration rate (CKD G4þ):
conclusions from a Kidney Disease: Improving Global Outcomes
(KDIGO) Controversies Conference. Kidney Int. 2018;93:1281–1292.
24. Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal
dysfunction and its impact on outcome in 118,465 patients hospitalized
with acute decompensated heart failure: a report from the ADHERE
database. J Card Fail. 2007;13:422–430.
25. Pandey A, Darden D, Berry JD. Low fitness in midlife: a novel
therapeutic target for heart failure with preserved ejection fraction
prevention. Prog Cardiovasc Dis. 2015;58:87–93.
26. Vanhecke TE, Franklin BA, Soman P, et al. Influence of myocardial
ischemia on outcomes in patients with systolic versus non-systolic
heart failure. Am J Cardiovasc Dis. 2011;1:167–175.Kidney International (2019) 95, 1304–131727. Vanhecke TE, Kim R, Raheem SZ, et al. Myocardial ischemia in patients
with diastolic dysfunction and heart failure. Curr Cardiol Rep. 2010;12:
216–222.
28. Unger ED, Dubin RF, Deo R, et al. Association of chronic kidney disease
with abnormal cardiac mechanics and adverse outcomes in patients
with heart failure and preserved ejection fraction. Eur J Heart Fail.
2016;18:103–112.
29. Hill SA, Booth RA, Santaguida PL, et al. Use of BNP and NT-proBNP for
the diagnosis of heart failure in the emergency department: a
systematic review of the evidence. Heart Fail Rev. 2014;19:421–438.
30. Colbert G, Jain N, de Lemos JA, et al. Utility of traditional circulating and
imaging-based cardiac biomarkers in patients with predialysis CKD. Clin
J Am Soc Nephrol. 2015;10:515–529.
31. DeFilippi CR, Fink JC, Nass CM, et al. N-terminal pro-B-type natriuretic
peptide for predicting coronary disease and left ventricular
hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney
Dis. 2005;46:35–44.
32. Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel 2004: a
clinical approach for the diagnostic, prognostic, screening, treatment
monitoring, and therapeutic roles of natriuretic peptides in
cardiovascular diseases. Congest Heart Fail. 2004;10:1–30.
33. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood
test for the evaluation and management of patients with heart failure.
Rev Cardiovasc Med. 2011;12:200–210.
34. Chawla LS, Herzog CA, Costanzo MR, et al. Proposal for a functional
classification system of heart failure in patients with end-stage renal
disease: proceedings of the acute dialysis quality initiative (ADQI) XI
workgroup. J Am Coll Cardiol. 2014;63:1246–1252.
35. Mueller-Lenke N, Rudez J, Staub D, et al. Use of chest radiography in the
emergency diagnosis of acute congestive heart failure. Heart. 2006;92:
695–696.
36. McCullough PA, Roberts WC. Influence of chronic renal failure on
cardiac structure. J Am Coll Cardiol. 2016;67:1183–1185.
37. Safley DM, Awad A, Sullivan RA, et al. Changes in B-type natriuretic
peptide levels in hemodialysis and the effect of depressed left
ventricular function. Adv Chronic Kidney Dis. 2005;12:117–124.
38. Aksut B, Starling R, Kapadia S. Stable coronary artery disease and left
ventricular dysfunction: the role of revascularization. Catheter
Cardiovasc Interv. 2017;90:777–783.
39. Upadhya B, Rocco M, Lewis CE, et al. Effect of intensive blood pressure
treatment on heart failure events in the systolic blood pressure
reduction intervention trial. Circ Heart Fail. 2017;10:e003613.
40. Rahman M, Ford CE, Cutler JA, et al. Long-term renal and cardiovascular
outcomes in Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated
GFR. Clin J Am Soc Nephrol. 2012;7:989–1002.
41. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal
and cardiovascular outcomes in patients with type 2 diabetes and
nephropathy. N Engl J Med. 2001;345:861–869.
42. He J, Shlipak M, Anderson A, et al. Risk factors for heart failure in
patients with chronic kidney disease: the CRIC (Chronic Renal
Insufficiency Cohort) study. J Am Heart Assoc. 2017;6. pii: e005336.
https://doi.org/10.1161/JAHA.116.005336.
43. Verma S, Juni P, Mazer CD. Pump, pipes, and filter: do SGLT2 inhibitors
cover it all? Lancet. 2019;393:3–5.
44. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and
secondary prevention of cardiovascular and renal outcomes in type 2
diabetes: a systematic review and meta-analysis of cardiovascular
outcome trials. Lancet. 2019;393:31–39.
45. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular
outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:
2117–2128.
46. Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical
outcomes in patients with type 2 diabetes mellitus, established
cardiovascular disease, and chronic kidney disease. Circulation.
2018;137:119–129.
47. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular
and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
48. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular
outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357.
49. Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce
cardiovascular mortality? Insights from a mediation analysis of the
EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:356–363.1315
KDIGO execu t i ve conc lu s i ons AA House et al.: HF in kidney disease: a KDIGO conference report50. Cleland JG, Pellicori P, Dierckx R. Clinical trials in patients with heart
failure and preserved left ventricular ejection fraction. Heart Fail Clin.
2014;10:511–523.
51. Cleland JG, Tendera M, Adamus J, et al. The Perindopril in Elderly
People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J. 2006;27:
2338–2345.
52. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure
with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392.
53. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin
inhibitor LCZ696 in heart failure with preserved ejection fraction: a
phase 2 double-blind randomised controlled trial. Lancet. 2012;380:
1387–1395.
54. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with
heart failure and preserved ejection fraction. N Engl J Med. 2008;359:
2456–2467.
55. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in
patients with chronic heart failure and preserved left-ventricular
ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–
781.
56. Ghali JK, Wikstrand J, Van Veldhuisen DJ, et al. The influence of renal
function on clinical outcome and response to beta-blockade in systolic
heart failure: insights from Metoprolol CR/XL Randomized Intervention
Trial in Chronic HF (MERIT-HF). J Card Fail. 2009;15:310–318.
57. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-
II): a randomised trial. Lancet. 1999;353:9–13.
58. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year
survival in dialysis patients with dilated cardiomyopathy: a prospective,
placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438–1444.
59. McDevitt DG. Comparison of pharmacokinetic properties of beta-
adrenoceptor blocking drugs. Eur Heart J. 1987;8(Suppl M):9–14.
60. Agarwal R, Sinha AD, Pappas MK, et al. Hypertension in hemodialysis
patients treated with atenolol or lisinopril: a randomized controlled
trial. Nephrol Dial Transplant. 2014;29:672–681.
61. Weir MA, Dixon SN, Fleet JL, et al. b-Blocker dialyzability and mortality
in older patients receiving hemodialysis. J Am Soc Nephrol. 2015;26:
987–996.
62. Edner M, Benson L, Dahlstrom U, et al. Association between renin-
angiotensin system antagonist use and mortality in heart failure with
severe renal insufficiency: a prospective propensity score-matched
cohort study. Eur Heart J. 2015;36:2318–2326.
63. Damman K, Perez AC, Anand IS, et al. Worsening renal function and
outcome in heart failure patients with preserved ejection fraction and
the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol.
2014;64:1106–1113.
64. Beldhuis IE, Streng KW, Ter Maaten JM, et al. Renin-angiotensin system
inhibition, worsening renal function, and outcome in heart failure
patients with reduced and preserved ejection fraction: a meta-analysis
of published study data. Circ Heart Fail. 2017;10. pii: e003588. https://
doi.org/10.1161/CIRCHEARTFAILURE.116.003588.
65. Damman K, Solomon SD, Pfeffer MA, et al. Worsening renal function
and outcome in heart failure patients with reduced and preserved
ejection fraction and the impact of angiotensin receptor blocker
treatment: data from the CHARM-study programme. Eur J Heart Fail.
2016;18:1508–1517.
66. Tokmakova MP, Skali H, Kenchaiah S, et al. Chronic kidney disease,
cardiovascular risk, and response to angiotensin-converting enzyme
inhibition after myocardial infarction: the Survival And Ventricular
Enlargement (SAVE) study. Circulation. 2004;110:3667–3673.
67. Damman K, Tang WH, Felker GM, et al. Current evidence on treatment
of patients with chronic systolic heart failure and renal insufficiency:
practical considerations from published data. J Am Coll Cardiol. 2014;63:
853–871.
68. Voors AA, Gori M, Liu LC, et al. Renal effects of the angiotensin receptor
neprilysin inhibitor LCZ696 in patients with heart failure and preserved
ejection fraction. Eur J Heart Fail. 2015;17:510–517.
69. Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap
between clinical guidelines and the utilization of renin-angiotensin-
aldosterone system inhibitors. Am J Manag Care. 2015;21(11 suppl):
S212–S220.
70. Pflugfelder PW, Baird MG, Tonkon MJ, et al. The Quinapril Heart Failure
Trial Investigators. Clinical consequences of angiotensin-converting
enzyme inhibitor withdrawal in chronic heart failure: a double-blind,
placebo-controlled study of quinapril. J Am Coll Cardiol. 1993;22:1557–
1563.131671. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with
acute decompensated heart failure. N Engl J Med. 2011;364:797–805.
72. Mentz RJ, Hasselblad V, DeVore AD, et al. Torsemide versus furosemide
in patients with acute heart failure (from the ASCEND-HF Trial). Am J
Cardiol. 2016;117:404–411.
73. Lopez B, Gonzalez A, Beaumont J, et al. Identification of a potential
cardiac antifibrotic mechanism of torasemide in patients with chronic
heart failure. J Am Coll Cardiol. 2007;50:859–867.
74. Eschalier R, McMurray JJ, Swedberg K, et al. Safety and efficacy of
eplerenone in patients at high risk for hyperkalemia and/or worsening
renal function: analyses of the EMPHASIS-HF study subgroups
(Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart
Failure). J Am Coll Cardiol. 2013;62:1585–1593.
75. Pitt B, Zannad F, Remme WJ, et al. Randomized Aldactone Evaluation
Study Investigators. The effect of spironolactone on morbidity and
mortality in patients with severe heart failure. N Engl J Med. 1999;341:
709–717.
76. Vardeny O, Wu DH, Desai A, et al. Influence of baseline and worsening
renal function on efficacy of spironolactone in patients with severe
heart failure: insights from RALES (Randomized Aldactone Evaluation
Study). J Am Coll Cardiol. 2012;60:2082–2089.
77. Quach K, Lvtvyn L, Baigent C, et al. The safety and efficacy of
mineralocorticoid receptor antagonists in patients who require dialysis:
a systematic review and meta-analysis. Am J Kidney Dis. 2016;68:591–
598.
78. Tseng WC, Liu JS, Hung SC, et al. Effect of spironolactone on the risks of
mortality and hospitalization for heart failure in pre-dialysis advanced
chronic kidney disease: a nationwide population-based study. Int J
Cardiol. 2017;238:72–78.
79. Filippatos G, Anker SD, Bohm M, et al. A randomized controlled study of
finerenone vs. eplerenone in patients with worsening chronic heart
failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J.
2016;37:2105–2114.
80. Rossignol P, Zannad F, Pitt B, et al. Time to retrieve the best benefits from
renin angiotensin aldosterone system (RAAS) inhibition in heart failure
patients with reduced ejection fraction: lessons from randomized controlled
trials and registries. Int J Cardiol. 2014;177:731–733.
81. Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing
serum potassium and preventing recurrent hyperkalaemia in patients
with heart failure and chronic kidney disease on RAAS inhibitors. Eur J
Heart Fail. 2015;17:1057–1065.
82. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium
cyclosilicate on potassium lowering for 28 days among outpatients
with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA.
2014;312:2223–2233.
83. Sterns RH, Grieff M, Bernstein PL. Treatment of hyperkalemia:
something old, something new. Kidney Int. 2016;89:546–554.
84. Brisco MA, Kimmel SE, Coca SG, et al. Prevalence and prognostic
importance of changes in renal function after mechanical circulatory
support. Circ Heart Fail. 2014;7:68–75.
85. Bansal N, Hailpern SM, Katz R, et al. Outcomes associated with left
ventricular assist devices among recipients with and without end-stage
renal disease. JAMA Intern Med. 2018;178:204–209.
86. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in
type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:
2019–2032.
87. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in
patients with heart failure and iron deficiency. N Engl J Med. 2009;361:
2436–2448.
88. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects
of long-term intravenous iron therapy with ferric carboxymaltose in
patients with symptomatic heart failure and iron deficiency. Eur Heart J.
2015;36:657–668.
89. Ponikowski P, Filippatos G, Colet JC, et al. The impact of intravenous
ferric carboxymaltose on renal function: an analysis of the FAIR-HF
study. Eur J Heart Fail. 2015;17:329–339.
90. Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric
carboxymaltose on hospitalisations and mortality rates in iron-deficient
heart failure patients: an individual patient data meta-analysis. Eur J
Heart Fail. 2018;20:125–133.
91. Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in
chronic kidney disease: conclusions from a “Kidney Disease: Improving
Global Outcomes” (KDIGO) Controversies Conference. Kidney Int.
2016;89:28–39.Kidney International (2019) 95, 1304–1317
AA House et al.: HF in kidney disease: a KDIGO conference report KD IGO execu t i ve conc lu s i ons92. Kerkela R, Karsikas S, Szabo Z, et al. Activation of hypoxia response in
endothelial cells contributes to ischemic cardioprotection. Mol Cell Biol.
2013;33:3321–3329.
93. EVOLVE Trial Investigators, Chertow GM, Block GA, Rotter-Correa R,
et al. Effect of cinacalcet on cardiovascular disease in patients
undergoing dialysis. N Engl J Med. 2012;367:2482–2494.
94. Korevaar JC, Feith GW, Dekker FW, et al. Effect of starting with
hemodialysis compared with peritoneal dialysis in patients new on
dialysis treatment: a randomized controlled trial. Kidney Int. 2003;64:
2222–2228.
95. McCullough PA, Chan CT, Weinhandl ED, et al. Intensive hemodialysis,
left ventricular hypertrophy, and cardiovascular disease. Am J Kidney
Dis. 2016;68(5S1):S5–S14.
96. Morfin JA, Fluck RJ, Weinhandl ED, et al. Intensive hemodialysis and
treatment complications and tolerability. Am J Kidney Dis. 2016;68(5S1):
S43–S50.
97. Burton JO, Jefferies HJ, Selby NM, et al. Hemodialysis-induced repetitive
myocardial injury results in global and segmental reduction in systolic
cardiac function. Clin J Am Soc Nephrol. 2009;4:1925–1931.
98. Odudu A, Eldehni MT, McCann GP, et al. Randomized controlled trial of
individualized dialysate cooling for cardiac protection in hemodialysis
patients. Clin J Am Soc Nephrol. 2015;10:1408–1417.
99. Wu C, Evans I, Joseph R, et al. Comorbid conditions in kidney
transplantation: association with graft and patient survival. J Am Soc
Nephrol. 2005;16:3437–3444.
100. Faravardeh A, Eickhoff M, Jackson S, et al. Predictors of graft failure and
death in elderly kidney transplant recipients. Transplantation. 2013;96:
1089–1096.
101. Siedlecki A, Foushee M, Curtis JJ, et al. The impact of left ventricular
systolic dysfunction on survival after renal transplantation.
Transplantation. 2007;84:1610–1617.
102. Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart
failure after kidney transplantation: a common condition with poor
prognostic implications. Am J Kidney Dis. 2005;46:720–733.
103. Lentine KL, Rocca-Rey LA, Bacchi G, et al. Obesity and cardiac risk after
kidney transplantation: experience at one center and comprehensive
literature review. Transplantation. 2008;86:303–312.
104. Rigatto C, Parfrey P, Foley R, et al. Congestive heart failure in renal
transplant recipients: risk factors, outcomes, and relationship with
ischemic heart disease. J Am Soc Nephrol. 2002;13:1084–1090.
105. Abbott KC, Hypolite IO, Hshieh P, et al. Hospitalized congestive heart
failure after renal transplantation in the United States. Ann Epidemiol.
2002;12:115–122.
106. Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin
North Am. 2004;88:1145–1172.
107. Young JB. The global epidemiology of heart failure. Med Clin North Am.
2004;88:1135–1143.
108. Filippatos GS, Desai RV, Ahmed MI, et al. Hypoalbuminaemia and
incident heart failure in older adults. Eur J Heart Fail. 2011;13:1078–
1086.
109. Abbott KC, Yuan CM, Taylor AJ, et al. Early renal insufficiency and
hospitalized heart disease after renal transplantation in the era of
modern immunosuppression. J Am Soc Nephrol. 2003;14:2358–2365.
110. Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation and
management among kidney and liver transplantation candidates: a
scientific statement from the American Heart Association and the
American College of Cardiology Foundation: endorsed by the
American Society of Transplant Surgeons, American Society of
Transplantation, and National Kidney Foundation. Circulation.
2012;126:617–663.Kidney International (2019) 95, 1304–1317111. Paoletti E, Cassottana P, Amidone M, et al. ACE inhibitors and persistent
left ventricular hypertrophy after renal transplantation: a randomized
clinical trial. Am J Kidney Dis. 2007;50:133–142.
112. Lentine KL, Villines TC, Axelrod D, et al. Evaluation and management of
pulmonary hypertension in kidney transplant candidates and recipients:
concepts and controversies. Transplantation. 2017;101:166–181.
113. Katz SD, Parikh CR. Reverse left ventricular remodeling after kidney
transplantation: unraveling the complex autointoxication of uremia.
J Am Coll Cardiol. 2015;66:1788–1790.
114. Wali RK,WangGS, Gottlieb SS, et al. Effect of kidney transplantation on left
ventricular systolic dysfunction and congestive heart failure in patients
with end-stage renal disease. J Am Coll Cardiol. 2005;45:1051–1060.
115. Hawwa N, Shrestha K, Hammadah M, et al. Reverse remodeling and
prognosis following kidney transplantation in contemporary patients
with cardiac dysfunction. J Am Coll Cardiol. 2015;66:1779–1787.
116. Parfrey PS, Harnett JD, Foley RN, et al. Impact of renal transplantation
on uremic cardiomyopathy. Transplantation. 1995;60:908–914.
117. Patel RK, Mark PB, Johnston N, et al. Renal transplantation is not
associated with regression of left ventricular hypertrophy: a magnetic
resonance study. Clin J Am Soc Nephrol. 2008;3:1807–1811.
118. Lai KN, Barnden L, Mathew TH. Effect of renal transplantation on left
ventricular function in hemodialysis patients. Clin Nephrol. 1982;18:74–78.
119. Fleming SJ, Caplin JL, Banim SO, et al. Improved cardiac function after
renal transplantation. Postgrad Med J. 1985;61:525–528.
120. Van Den Broek JH, Boxall JA, Thomson NM. Improved left ventricular
function after renal transplantation. Med J Aust. 1991;154:279–280.
121. Abouna GM, Kumar MS, Silva OS, et al. Reversal of myocardial
dysfunction following renal transplantation. Transplant Proc. 1993;25:
1034–1035.
122. Sahagun-Sanchez G, Espinola-Zavaleta N, Lafragua-Contreras M, et al.
The effect of kidney transplant on cardiac function: an
echocardiographic perspective. Echocardiography. 2001;18:457–462.
123. Melchor JL, Espinoza R, Gracida C. Kidney transplantation in patients
with ventricular ejection fraction less than 50 percent: features and
posttransplant outcome. Transplant Proc. 2002;34:2539–2540.
124. Oppert M, Schneider U, Bocksch W, et al. Improvement of left
ventricular function and arterial blood pressure 1 year after
simultaneous pancreas kidney transplantation. Transplant Proc. 2002;34:
2251–2252.
125. Dudziak M, Debska-Slizien A, Rutkowski B. Cardiovascular effects of
successful renal transplantation: a 30-month study on left ventricular
morphology, systolic and diastolic functions. Transplant Proc. 2005;37:
1039–1043.
126. Vaidya OU, House JA, Coggins TR, et al. Effect of renal transplantation
for chronic renal disease on left ventricular mass. Am J Cardiol.
2012;110:254–257.
127. Burt RK, Gupta-Burt S, Suki WN, et al. Reversal of left ventricular
dysfunction after renal transplantation. Ann Intern Med. 1989;111:635–
640.
128. Schaffer JM, Chiu P, Singh SK, et al. Heart and combined heart-
kidney transplantation in patients with concomitant renal
insufficiency and end-stage heart failure. Am J Transplant. 2014;14:
384–396.
129. Kilic A, Grimm JC, Whitman GJ, et al. The survival benefit
of simultaneous heart-kidney transplantation extends
beyond dialysis-dependent patients. Ann Thorac Surg. 2015;99:
1321–1327.
130. Collins AJ, Foley R, Herzog C, et al. Excerpts from the United States
Renal Data System 2007 annual data report. Am J Kidney Dis. 2008;51:
S1–S320.1317
